Sphere Fluidics, a Cambridge, England, UK-based company commercializing single cell analysis systems, closed a $2m (circa £1.5m) funding round.
Backers included Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket.
The funds raised will be used to accelerate growth in operations and support sales across the UK and USA (opening a new US West Coast Sales Office) of its Cyto-Mine® Single Cell Analysis System.
Led by Frank F Craig PhD MBA, CEO, Sphere Fluidics provides Cyto-Mine, an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. It can process up to 40 million cells per day, and assesses and isolates those that produce a specific biologic to help streamline workflows and improve throughput in antibody discovery and cell line development.